Table 3. Summary of included retrospective and epidemiological studies.

N = number of MPXV-positive patients, NR = not reported; PCR = polymerase chain reaction

Author, Year	N	Mean Age	Gender, % male	Pain prevalence	Pain Initial Symptom?	Pain Region	Pain Intensity	Method of diagnosis	Treatment
Ogoina, 2022 [27]	40	37	77.5%	Not reported	Yes	NR	NR	Clinical judgement of the attending physician	NR
Girometti, 2022 [28]	54	41	100%	Inpatient treatment for severe pain (n=5)	No	Disseminated presentation	Severe. No score reported	PCR	Analgesia.  Not described
De Baetselier, 2022 [29]	4	NR	100%	Painful vesicular rash (n=1)	Yes	Perianal rash	NR	PCR	NR
Huhn, 2005 [30]	34	26	53%	Headache (65%) Myalgias (56%)	No	Mouth sores	NR	Viral culture PCR Electron microscopy Immuno-histochemistry	NR
Croft, 2007 [31]	19	28	76%	Headache (n=13) Joint pain (n=6)	NR	NR	NR	PCR Immuno-histochemistry Virus culture Electron microscopy	NR
Yinka-Ogunleye, 2019 [32]	122	29	69%	Headache (n=61) Myalgia (n=42) Sore throat (n=45)	No	NR	NR	PCR IgM	NR